CNTA - CIK 0001847903
Centessa Pharmaceuticals plc (CNTA) reported net income of -$197.53M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$197.53M | +16.2% |
| FY 2024 | -$235.76M | -56.0% |
| FY 2023 | -$151.09M | +30.1% |
| FY 2022 | -$216.21M | +43.3% |
| FY 2021 | -$381.07M | -3473.8% |
| FY 2020 | -$10.66M | -110.7% |
| FY 2019 | -$5.06M | - |
Centessa Pharmaceuticals plc (CNTA) reported net income of -$197.53M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Centessa Pharmaceuticals plc's net income declined from -$5.06M to -$197.53M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.